Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
International Journal of Molecular Sciences · 09.09.2023 · 24 (18) · 13900
DOI: 10.3390/ijms241813900 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.09.2023. Verfasst von Francesca R Buccellato und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 207 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health.
Themen: Demenz
Abstract (Originalsprache)
In an ever-increasing aged world, Alzheimer’s disease (AD) represents the first cause of dementia and one of the first chronic diseases in elderly people. With 55 million people affected, the WHO considers AD to be a disease with public priority. Unfortunately, there are no final cures for this pathology. Treatment strategies are aimed to mitigate symptoms, i.e., acetylcholinesterase inhibitors (AChEI) and the N-Methyl-D-aspartate (NMDA) antagonist Memantine. At present, the best approaches for managing the disease seem to combine pharmacological and non-pharmacological therapies to stimulate cognitive reserve. Over the last twenty years, a number of drugs have been discovered acting on the well-established biological hallmarks of AD, deposition of β-amyloid aggregates and accumulation of hyperphosphorylated tau protein in cells. Although previous efforts disappointed expectations, a new era in treating AD has been working its way recently. The Food and Drug Administration (FDA) gave conditional approval of the first disease-modifying therapy (DMT) for the treatment of AD, aducanumab, a monoclonal antibody (mAb) designed against Aβ plaques and oligomers in 2021, and in January 2023, the FDA granted accelerated approval for a second monoclonal antibody, Lecanemab. This review describes ongoing clinical trials with DMTs and non-pharmacological therapies. We will also present a future scenario based on new biomarkers that can detect AD in preclinical or prodromal stages, identify people at risk of developing AD, and allow an early and curative treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy.
ORCID-Profile: Marianna D'Anca, Massimo Del Fabbro, Daniela Galimberti
Förderung
- Ministero della Salute
- Italian Ministry of Health
Zitieren
APA
Buccellato, F. R., D'Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023). Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies. International Journal of Molecular Sciences, 24(18), 13900. https://doi.org/10.3390/ijms241813900
Vancouver
Buccellato FR, D'Anca M, Tartaglia GM, Del Fabbro M, Scarpini E, Galimberti D. Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies. International Journal of Molecular Sciences. 2023;24(18):13900. doi:10.3390/ijms241813900
BibTeX
@article{Buccellato2023,
author = {Buccellato, Francesca R and D'Anca, Marianna and Tartaglia, Gianluca Martino and Del Fabbro, Massimo and Scarpini, Elio and Galimberti, Daniela},
title = {Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {18},
pages = {13900},
doi = {10.3390/ijms241813900}
}
EUVIMED